Testing effectiveness (Phase 2)Study completedNCT01030900
What this trial is testing
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Who this might be right for
Hodgkin LymphomaDiffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 50